Form 4: Amylyx CMO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 12,039 shares of common stock to cover tax withholding obligations.

Summary

• Camille L. Bedrosian, Chief Medical Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported a sale of common stock.
• The transaction involved the disposition of 12,039 shares of common stock.
• The shares were sold at a weighted average price of $14.5791 per share, with prices ranging from $14.35 to $15.04.
• The sale was executed on September 30, 2025.
• The purpose of the sale was to cover tax withholding obligations related to the vesting of restricted stock units.
• The sales were automatic and not at the discretion of the Reporting Person.
• Following this transaction, Camille L. Bedrosian directly beneficially owns 182,336 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents an automatic, non-discretionary sale to cover tax obligations associated with equity compensation, rather than a discretionary investment decision.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Management Comments

• The shares were required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This Form 4 filing details a routine insider transaction, specifically an automatic sale of shares to cover tax obligations upon the vesting of restricted stock units. Such transactions are common across all industries for executives receiving equity compensation and do not typically reflect a change in sentiment towards the company's prospects or broader industry trends.

Stakeholder Impact

• Shareholders: The sale is a routine, non-discretionary event for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's operational outlook.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Camille L. Bedrosian, Chief Medical Officer, Insider Trading, Stock Sale, Form 4, Tax Withholding, Restricted Stock Units, Equity Compensation